Patent US4665098A successfully refreshed from Google Patents.
US4665098A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical composition of N-(4-hydroxyphenyl) retinamide having increased bioavailability
Assignee: Janssen Pharmaceuticals Inc
•
Filing: 1985-03-28
•
Granted: 1987-05-12
•
Expires: 2005-03-28
Abstract
Abstract A dosage of N-(4-hydroxyphenyl)retinamide, also known as fenretimide, of the following formula: ##STR1## with increased bioavailability comprising corn oil and a non-ionic surfactant. The formulation if useful in the treatment of breast or bladder cancer, psoriasis and acne.
Inventors
- 👤 Irwin S. Gibbs
- 👤 Pramod M. Kotwal
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-31 14:26
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/16; A61K31/165; A61K47/00; A61K47/44; A61K9/00; A61K9/48; A61K9/4841; A61K9/4858; A61P; A61P17/00; A61P35/00
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
74 words
A pharmaceutical dosage form which comprises a soft gelatin capsule for oral administration containing in the hollow interior thereof, a pharmaceutical composition which comprises a suspension of the following components: (i) a pharmaceutically effective amount for the treatment of breast cancer, bladder cancer, acne or psoriasis of N-(4-hydroxyphenyl)retinamide of the following formula: ##STR4## (ii) corn oil; and (iii) a non-ionic surfactant, wherein the weight ratio of component (ii):component (iii) is about 5:1 to 50:1.
Claim 2
Dependent Claim
74 words
A pharmaceutical dosage form which comprises a soft gelatin capsule for oral administration containing in the hollow interior thereof, a pharmaceutical composition which comprises a suspension of the following components: (i) a pharmaceutically effective amount for the treatment of breast cancer, bladder cancer, acne or psoriasis of N-(4-hydroxyphenyl)retinamide of the following formula: ##STR4## (ii) corn oil; and (iii) a non-ionic surfactant, wherein the weight ratio of component (ii):component (iii) is about 5:1 to 50:1.
Claim 3
Dependent Claim
20 words
The pharmaceutical dosage form of claim 1, wherein the weight ratio of component (ii):component (iii) is about 10:1 to 15:1.
Claim 4
Dependent Claim
22 words
The pharmaceutical dosage form of claim 1, wherein the mean size of the particles of component (i) is below about 70 microns.
Claim 5
Dependent Claim
24 words
The pharmaceutical dosage form of claim 3, wherein the mean size of the particles of component (i) is from about 0.5 to 50 microns.
Claim 6
Dependent Claim
47 words
The pharmaceutical dosage form of claim 1, wherein said component (iii) is a member of one of the groups consisting of polyethylene sorbitan fatty acid esters, sorbitan fatty acid esters, polyoxyethylene alcohols, polyoxyethylene acids, polyoxyethylene-polyoxypropylene glycols, polyoxyethylated vegetable oils, monoglycerides, diglycerides, polyoxyethylene sorbitol esters, and the polysorbates.
Claim 7
Dependent Claim
14 words
The pharmaceutical dosage form of claim 5, wherein said component (iii) is a polysorbate.
Claim 8
Dependent Claim
14 words
The pharmaceutical dosage form of claim 6, wherein said component (iii) is polysorbate 80.
Claim 9
Dependent Claim
36 words
A method for the treatment of breast cancer, bladder cancer, psoriasis or acne which comprises administering to a mammal in need of such treatment, a pharmaceutically effective amount of the pharmaceutical dosage form of claim 1.
Claim 10
Dependent Claim
18 words
The method of claim 8, wherein said method is for the treatment of breast cancer or bladder cancer.
Claim 11
Dependent Claim
11 words
The method of claim 9, wherein said cancer is bladder cancer.
Claim 12
Dependent Claim
11 words
The method of claim 8, wherein said mammal is a human.
Claim 13
Dependent Claim
12 words
The method of claim 8, wherein said administration is with a meal.
Claim 14
Dependent Claim
12 words
The method of claim 12, wherein said meal is high in lipids.
References Cited (Backward Citations)
US4190594A
Cited
US4323581A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-05-11 | 1990-11-10 | 1991-05-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-05-11 | 1994-11-10 | 1995-05-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-05-11 | 1998-11-10 | 1999-05-12 | $7700.00 | Window Closed / Lapsed |